Mr. Larkin further added, "Dr. Dinarello has generated significant interest in other immunological disease opinion leaders in determining the potential use of AAT as a potential therapy for additional immunological disease classifications. As a result of his efforts and key relationships with investigators at well-known academic and research institutions, we are currently in discussions with a number of institutions on pursuing human clinical trials in other disease classifications. We expect to provide further clarification on these prospective trials if preliminary commitments from the trial institutions are obtained."
About Omni Bio Pharmaceutical, Inc.
Omni Bio Pharmaceutical, Inc. (www.omnibiopharma.com) is an emerging biopharmaceutical company formed to acquire, license, and develop existing therapies for indications with substantial commercialization potential. Omni Bio's core technology and pipeline are based on issued and pending patents licensed from the University of Colorado Denver ("UCD") and a privately held corporation surrounding the broader therapeutic potential of currently marketed therapies. One of Omni Bio's lead development programs is evaluating an FDA-approved, off-patent drug, AAT, for the treatment
|SOURCE Omni Bio Pharmaceutical, Inc.|
Copyright©2010 PR Newswire.
All rights reserved